Skip to main content

Table 1 The characteristics of included studies

From: Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis

Author Year Local Sample size Age# of intervention group Age of Control group Abbreviations Intervention Control Follow-up
Bhatt [28] 2019 Multination 8179 64 (57–69) 64 (57–69) REDUCE-IT EPA Placebo 4.9 Years
Ouchi [29] 2019 Japan 1046 80.6 ± 4.7 80.6 ± 4.7 EWTOPIA 75 Ezetimibe Control 5 Years
Elam [30] 2016 US,Canada 3635 62.3 ± 6.8 62.3 ± 6.8 ACCORD Fenofibrate Placebo 4.7 Years
Arbel [31] 2016 Israel 458 58 ± 7 58 ± 7 BIP Bezafibrate Placebo 20 Years
Kalil [32] 2015 US 3413 70.8 ± 7.4 70.6 ± 7.2 AIM-HIGH Niacin Placebo 4.1 Years
Landray [33] 2014 UK,Scandinavia,China 6575 64.9 ± 7.5 64.9 ± 7.5 HPS2-THRIVE Niacin plus laropiprant Placebo 3.9 Years
Davidson [34] 2014 US 676 61 () 61 (?) FIRST Fenofibrate Placebo 108 Weeks
The ORIGIN Trial
Investigators [35]
2012 Canada 4270 63.5 ± 7.8 63.6 ± 7.9 ORIGIN Omega-3 fatty acid Placebo 6.2 Years
Amarenco [36] 2008 Multinational 1575 63.0 ± 0.2 62.5 ± 0.2 SPARCL Atorvastatin Placebo 4.9 Years
Yokoyama [37] 2007 Japan 9211 61 ± 8 61 ± 9 JELIS EPA Control 5 Years
The FIELD study investigators [38] 2005 Multinations 5093 62.2 ± 6.9 62.2 ± 6.8 FIELD Fenofibrate Placebo 5 Years
Colhoun [39] 2004 UK, Ireland 1425 61.8 ± 8.0 61.5 ± 8.3 CARDS Atorvastatin Placebo 4 Years
Sasaki [40] 2002 Japan 497 55.5 ± 10.2 55.5 ± 10.1 NA Pravastatin Control 5 Years
Ballantyne [41] 2001 Multinations 458 57.7 ± 7.8 57.7 ± 7.8 4S Simvastatin Placebo 5.4 Years
Durrington [42] 2000 UK 59 55.2 ± 7.0 54.8 ± 10.2 NA Omega-3 fatty acid Placebo 1 Year
Rubins [43] 1999 US 1185 64 ± 7 64 ± 7 VA-HIT Gemfibrozil Placebo 5.1 Years
Tonkin [44] 1998 Australia, New Zealand 1490 62 (55–67) 62 (55–68) LIPID Pravastatin Placebo 6.1 Years
Sacks [45] 1996 US, Canada 2079 59 ± 9 59 ± 9 CARE Pravastatin Placebo 5 Years
Shepherd [46] 1995 UK 3356 55.3 ± 5.5 55.1 ± 5.5 WSCPS Pravastatin Placebo 4.9 Years
Carlson [47] 1988 Sweden 301 Males 59.2 ± 0.4
Female 63.0 ± 0.7
Male 58.9 ± 0.4
Females 62.5 ± 0.9
SIHDSPS Niacin plus Clofibrate Control 5 Years
Manninen [48] 1988 Finland 1490 NA (40–55) NA (40–55) HHS Gemfibrozil Placebo 5 Years
  1. NA not available, EPA eicosapentaenoic acid. The full name of abbreviation for each study and the detail of major adverse cardiovascular events assessment were list in Additional file 2: Table S2
  2. #Average age showed as: Mean ± Standard deviation or median (minimum–maximum)